Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity

Oncogene

Volumn 28, Issue 4, 2009, Pages 518-533

  Tang, Z ^a   Jiang, S ^a   Du, R ^a   Petri, E T ^b   El Telbany, A ^a   Chan, P S O ^c   Kijima, T ^d   Dietrich, S ^a   Matsui, K ^e   Kobayashi, M ^e   Sasada, S ^e   Okamoto, N ^e   Suzuki, H ^e   Kawahara, K ^e   Iwasaki, T ^e   Nakagawa, K ^e   Kawase, I ^d   Christensen, J G ^f   Hirashima, T ^e   Halmos, B ^a   Salgia, R ^g   Boggon, T J ^b   Kern, J A ^a   Ma, P C ^a   more..

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Elpidex Bioscience Inc   (United States)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^f PFIZER INC   (United States)

^g University of Chicago   (United States)

Author keywords

EGFR; Kinome; MET; Mutation; Structure; Tyrosine kinase inhibitor

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE;

ARTICLE; CELL PROLIFERATION; CONFORMATION; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ION PAIR EXTRACTION; LUNG CANCER; MENINGEAL METASTASIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS;

AMINO ACID SUBSTITUTION; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; FOCAL ADHESION KINASE 1; HUMANS; INDOLES; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION, MISSENSE; PIPERAZINES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; SULFONAMIDES;

EID: 59149088850     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.411     Document Type: Article

References (41)

1. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L et al. (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937.
2. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K et al. (2008). c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma related mutations. J Biol Chem 283: 2675-2683.
3. Brodsky LI, Vasiliev AV, Kalaidzidis YL, Osipov YS, Tatuzov RL, Feranchuk SI. (1992). GeneBee: the program package for biopolymer structure analysis. Dimacs 8: 127-139.
4. Chen Z, Feng J, Saldivar JS, Gu D, Bockholt A, Sommer SS (2008). EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene 27: 4336-4343.
5. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC et al. (2006). Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat Clin Pract Oncol 3: 50-57; quiz 51 p following 57.
6. Clamp M, Cuff J, Searle SM, Barton GJ. (2004). The Jalview Java alignment editor. Bioinformatics 20: 426-427.
7. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD et al. (2000). Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19: 1547-1555.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
9. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA et al. (2007). Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12: 501-513.
10. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. (2008). Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692-697.
11. Hubbard SR. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. Embo J 16: 5572-5581.
12. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM et al. (2006). Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24: 4517-4520.
13. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V et al. (2006). Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361.
14. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. (2007). LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
15. Jin L, Pluskey S, Petrella EC, Cantin SM, Gorga JC, Rynkiewicz MJ et al. (2004). The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors. J Biol Chem 279: 42818-42825.
16. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47(Part 2): 110-119.
17. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
18. Krause DS, Van Etten RA. (2005). Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187.
19. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y et al. (2005). Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
21. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al. (2005a). Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65: 1479-1488.
22. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD et al. (2003a). c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281.
23. Ma PC, Maulik G, Christensen J, Salgia R. (2003b). c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22: 309-325.
24. Ma PC, Schaefer E, Christensen JG, Salgia R. (2005b). A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 11: 2312-2319.
25. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. (2007). Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97: 368-377.
26. Mazzone M, Comoglio PM. (2006). The Met pathway: master switch and drug target in cancer progression. FASEB J 20: 1611-1621.
27. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
28. Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657-3660.
29. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L et al. (2004). 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem 47: 3367-3380.
30. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
31. Scapin G, Patel SB, Lisnock J, Becker JW, LoGrasso PV. (2003). The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol 10: 705-712.
32. Shigematsu H, Gazdar AF. (2006). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262.
33. Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW et al. (2004). RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 64: 7962-7970.
34. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H et al. (2006). Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103: 2316-2321.
35. Stamos J, Sliwkowski MX, Eigenbrot C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272.
36. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK et al. (2006). Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653.
37. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J et al. (2008). Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99: 911-922, 2008.
38. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351.
39. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH et al. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
40. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
41. Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM et al. (1999). Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 7: 651-661.